FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2558801610> ?p ?o ?g. }

• W2558801610 endingPage "144" @default.
• W2558801610 startingPage "137" @default.
• W2558801610 abstract "Eribulin, a microtubule dynamics inhibitor, is approved for the treatment of patients with breast cancer and soft tissue sarcoma. We investigated the efficacy and safety of eribulin in Japanese patients with soft tissue sarcoma. This open-label, multicenter, nonrandomized, Phase 2 study enrolled Japanese patients with measurable, advanced/metastatic soft tissue sarcoma of high/intermediate grade and ≥1 prior chemotherapy for advanced disease. Patients received eribulin mesilate 1.4 mg/m2 intravenously over 2–5 minutes on Days 1 and 8 of a 21-day cycle. The primary endpoint was progression-free rate at 12 weeks. Secondary endpoints included overall survival, progression-free survival and safety. Efficacy analyses were stratified by histology (liposarcoma or leiomyosarcoma, and other subtypes). Overall, 52 patients were enrolled and 51 patients were treated. Patients with liposarcoma/leiomyosarcoma (n = 35) had similar characteristics to those with other subtypes (n = 16), except for a higher proportion of women (63% vs 38%, respectively) and patients with Eastern Cooperative Oncology Group performance status 0 (57% vs 44%). Progression-free rate at 12 weeks was 60% in liposarcoma/leiomyosarcoma patients, 31% in other subtypes and 51% overall. Median progression-free survival was 5.5 months in liposarcoma/leiomyosarcoma patients, 2.0 months in other subtypes and 4.1 months overall. Median overall survival was 17.0 months in liposarcoma/leiomyosarcoma patients, 7.6 months in other subtypes and 13.2 months overall. The most common Grade 3–4 adverse events were neutropenia (86%), leukopenia (75%), lymphopenia (33%), anemia (14%) and febrile neutropenia (8%). Eribulin showed clinical activity with a manageable safety profile in previously treated Japanese patients with advanced/metastatic soft tissue sarcoma." @default.
• W2558801610 created "2016-12-08" @default.
• W2558801610 creator A5005444399 @default.
• W2558801610 creator A5012625833 @default.
• W2558801610 creator A5013302924 @default.
• W2558801610 creator A5034145578 @default.
• W2558801610 creator A5036726875 @default.
• W2558801610 creator A5036808755 @default.
• W2558801610 creator A5051892769 @default.
• W2558801610 creator A5061154739 @default.
• W2558801610 creator A5064272098 @default.
• W2558801610 creator A5069426624 @default.
• W2558801610 creator A5070380363 @default.
• W2558801610 date "2016-12-01" @default.
• W2558801610 modified "2023-10-14" @default.
• W2558801610 title "Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma†" @default.
• W2558801610 cites W1761376684 @default.
• W2558801610 cites W1883812557 @default.
• W2558801610 cites W1918894023 @default.
• W2558801610 cites W1955072209 @default.
• W2558801610 cites W2018563247 @default.
• W2558801610 cites W2019607817 @default.
• W2558801610 cites W2057195209 @default.
• W2558801610 cites W2060665573 @default.
• W2558801610 cites W2079678302 @default.
• W2558801610 cites W2088303301 @default.
• W2558801610 cites W2101776780 @default.
• W2558801610 cites W2107230638 @default.
• W2558801610 cites W2112169652 @default.
• W2558801610 cites W2117431699 @default.
• W2558801610 cites W2117905001 @default.
• W2558801610 cites W2129288285 @default.
• W2558801610 cites W2134549022 @default.
• W2558801610 cites W2145238269 @default.
• W2558801610 cites W2259955047 @default.
• W2558801610 cites W2989800034 @default.
• W2558801610 cites W4244970282 @default.
• W2558801610 doi "https://doi.org/10.1093/jjco/hyw175" @default.
• W2558801610 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5943671" @default.
• W2558801610 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28173193" @default.
• W2558801610 hasPublicationYear "2016" @default.
• W2558801610 type Work @default.
• W2558801610 sameAs 2558801610 @default.
• W2558801610 citedByCount "43" @default.
• W2558801610 countsByYear W25588016102017 @default.
• W2558801610 countsByYear W25588016102018 @default.
• W2558801610 countsByYear W25588016102019 @default.
• W2558801610 countsByYear W25588016102020 @default.
• W2558801610 countsByYear W25588016102021 @default.
• W2558801610 countsByYear W25588016102022 @default.
• W2558801610 countsByYear W25588016102023 @default.
• W2558801610 crossrefType "journal-article" @default.
• W2558801610 hasAuthorship W2558801610A5005444399 @default.
• W2558801610 hasAuthorship W2558801610A5012625833 @default.
• W2558801610 hasAuthorship W2558801610A5013302924 @default.
• W2558801610 hasAuthorship W2558801610A5034145578 @default.
• W2558801610 hasAuthorship W2558801610A5036726875 @default.
• W2558801610 hasAuthorship W2558801610A5036808755 @default.
• W2558801610 hasAuthorship W2558801610A5051892769 @default.
• W2558801610 hasAuthorship W2558801610A5061154739 @default.
• W2558801610 hasAuthorship W2558801610A5064272098 @default.
• W2558801610 hasAuthorship W2558801610A5069426624 @default.
• W2558801610 hasAuthorship W2558801610A5070380363 @default.
• W2558801610 hasBestOaLocation W25588016101 @default.
• W2558801610 hasConcept C121608353 @default.
• W2558801610 hasConcept C126322002 @default.
• W2558801610 hasConcept C136948725 @default.
• W2558801610 hasConcept C141071460 @default.
• W2558801610 hasConcept C142724271 @default.
• W2558801610 hasConcept C143998085 @default.
• W2558801610 hasConcept C203092338 @default.
• W2558801610 hasConcept C2775930923 @default.
• W2558801610 hasConcept C2776387010 @default.
• W2558801610 hasConcept C2776694085 @default.
• W2558801610 hasConcept C2777063308 @default.
• W2558801610 hasConcept C2777532014 @default.
• W2558801610 hasConcept C2778256501 @default.
• W2558801610 hasConcept C2778629024 @default.
• W2558801610 hasConcept C2779568860 @default.
• W2558801610 hasConcept C530470458 @default.
• W2558801610 hasConcept C535046627 @default.
• W2558801610 hasConcept C71924100 @default.
• W2558801610 hasConcept C90924648 @default.
• W2558801610 hasConceptScore W2558801610C121608353 @default.
• W2558801610 hasConceptScore W2558801610C126322002 @default.
• W2558801610 hasConceptScore W2558801610C136948725 @default.
• W2558801610 hasConceptScore W2558801610C141071460 @default.
• W2558801610 hasConceptScore W2558801610C142724271 @default.
• W2558801610 hasConceptScore W2558801610C143998085 @default.
• W2558801610 hasConceptScore W2558801610C203092338 @default.
• W2558801610 hasConceptScore W2558801610C2775930923 @default.
• W2558801610 hasConceptScore W2558801610C2776387010 @default.
• W2558801610 hasConceptScore W2558801610C2776694085 @default.
• W2558801610 hasConceptScore W2558801610C2777063308 @default.
• W2558801610 hasConceptScore W2558801610C2777532014 @default.
• W2558801610 hasConceptScore W2558801610C2778256501 @default.
• W2558801610 hasConceptScore W2558801610C2778629024 @default.
• W2558801610 hasConceptScore W2558801610C2779568860 @default.

• next